uniQure N.V.

uniQure N.V. is a gene therapy company that engages in the development of treatments for patients suffering from genetic and other devastating diseases. It is headquartered in Amsterdam, the Netherlands, and was founded in 1998. The company’s lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. uniQure is also developing a number of other treatments, including AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

uniQure has become a leader in gene therapy, with its therapies being developed to treat a wide range of diseases. The company is committed to using its scientific expertise to develop treatments that can improve the lives of patients. To achieve this, uniQure has established collaborations with leading academic partners, biotechnology companies, and pharmaceutical companies. uniQure also has its own research and development capabilities, and has access to cutting-edge technologies, such as gene editing, gene transfer, and gene expression.

In addition to its research and development activities, uniQure is also actively engaged in commercialization efforts. The company is focused on expanding its commercial presence in Europe, the United States, and other countries, and has established a number of strategic partnerships. uniQure has also established a number of manufacturing facilities to ensure that its products are made to the highest standards.

uniQure is committed to creating value for both its shareholders and the patients it serves. The company has a strong financial position, with a market capitalization of $2.1 billion as of April 2021. uniQure has also received a number of awards and recognitions, including being named one of the 2020 Red Herring Top 100 Global Companies and being named one of the 2021 FierceBiotech Fierce 15 Companies.